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DNAAbstract Congenital heart disease (CHD) is the most frequent birth defect (0.8%–1% of all live
births). Due to the advance in prenatal and postnatal early diagnosis and treatment, more than
90% of these patients survive into adulthood today. However, several mid- and long-term morbidi-
ties are dominating the follow-up of these patients. Due to the rarity and heterogeneity of the phe-
notypes of CHD, multicenter registry-based studies are required. The CHD-Biobank was
established in 2009 with the aim to collect DNA from patients and their parents (trios) or from
affected families, as well as cardiovascular tissues from patients undergoing corrective heart surgery
for cardiovascular malformations. Clinical/phenotype data are matched to the International
Paediatric and Congenital Cardiac Code (IPCCC) and the International Statistical Classiﬁcation
of Diseases and Related Health Problems 10th Revision (ICD-10). The DNA collection currently
comprises samples from approximately 4200 participants with a wide range of CHD phenotypes.
The collection covers about 430 trios and 120 families with more than one affected member. The
cardiac tissue collection comprises 1143 tissue samples from 556 patients after open heart surgery.nces and
182 Genomics Proteomics Bioinformatics 14 (2016) 181–190The CHD-Biobank provides a comprehensive basis for research in the ﬁeld of CHD with high
standards of data privacy, IT management, and sample logistics.Steering Committee
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Figure 1 Structure of CNCHD and NRCHDIntroduction
Congenital heart disease (CHD) is the most common congen-
ital organ malformation in the neonate. The prevalence of
CHD is nearly stable and ranges from 8–10/1000 [1,2]. Due
to the rapid improvement in prenatal and postnatal early diag-
nosis, as well as the advance in interventional, surgical, and
postoperative treatment, the survival of offsprings with CHD
has increased dramatically in the last two decades [3–6]. Nev-
ertheless, in moderate and severe congenital heart defects,
anatomical correction could not be achieved. Intracardiac
and extracardiac anatomical and functional residual defects
which lead to mid- and long-term morbidities are still challeng-
ing and limit the long-term survival and quality of life of these
patients [7].
The etiology of CHD, which is complex and associated with
both genetic and environmental causes, is still largely unknown
[8,9]. With the growing number of adult CHD patients, infor-
mation on recurrence risks and understanding the etiology will
become increasingly important. Despite the introduction of
novel genetic techniques such as next-generation sequencing
(NGS), the molecular and genetic mechanisms underlying the
development of CHD have not been clearly elucidated yet
and the identiﬁcation of particular defects remains challenging
[10,11].
Moreover, in contrast to the intensive research in the ﬁeld
of ischemic heart failure and the development of therapeutic
and preventive approaches in adult patients, the therapeutic
and preventive strategies for heart failure in patients with
CHD are not adequately established. The molecular mecha-
nisms of myocardial failure in neonatal myocardium after
corrective surgery using the cardiopulmonary bypass (CPB),
as well as in patients with residual pressure and volume over-
load, have not been clearly identiﬁed yet [12].
The rarity of such congenital diseases and their heteroge-
neous morphological phenotypic and morphological manifes-
tation make it difﬁcult to study molecular and genetic origin
as well as prevention and treatment [13]. Therefore, CHD
and its surgical correction are still associated with high mortal-
ity in the neonatal life, in contrast to older age groups [14,15].
Although the neonatal myocardium may still have protec-
tive remodeling capacities such as stem cell and myocyte
proliferation [16,17], the vulnerability of the neonatal myocar-
dium to ischemia and other risk factors during the surgical
manipulation and extracorporeal perfusion by CPB may repre-
sent signiﬁcant risk factors [18,19], leading to myocardial
dysfunction after heart surgery. On the other hand, residual
adaptive mechanisms of the fetal heart such as cell prolifera-
tion and the presence of stem cells have been considered as
possible adaptive capacities against stress and ischemic injury
[16,17]. Data on the remodeling processes in these patients dur-
ing the transition from fetal to neonatal life are scarce and
should be evaluated within the biobank on the basis of a stan-
dardized collection of myocardial tissues.
Thus, the establishment of a nationwide research platform
to overcome such challenges in the most common congenital
organ malformations in the future is urgently needed.Moreover, extensive research cooperation should not be lim-
ited to nationwide research groups, but should also be
extended to other countries and performed on an international
level, as demonstrated by our network during the past ﬁve
years (see below, section ‘‘Cooperative projects and partner
institutions”).
Network and biobank infrastructure
The CHD-Biobank is an integral part of the National Register
for Congenital Heart Defects (www.kompetenznetz-ahf.de/en/
research/register-biobank, hereafter NRCHD), which serves as
a core facility of the German Competence Network for Con-
genital Heart Defects (www.kompetenznetz-ahf.de/en/home,
hereafter CNCHD). Both entities are non-proﬁt organizations
and operate independently of each other, thus guaranteeing
the separation of sustainable and long-term patient data
administration and storage on the one hand and research
activities on the other hand (Figure 1). The management and
coordination for both entities are performed by a central
ofﬁce, the Network Management Ofﬁce (NMO). The NMO
is responsible for patient registration, administration, and con-
sent management. It is also responsible for sample collection,
validation of clinical/phenotype data, and research/study man-
agement, as well as network communication and operation of
database systems. The whole network is headed by a Steering
Committee that includes board members from both NRCHD
and CNCHD. An essential element of the CHD-Biobank
infrastructure is the cooperation with the Central Biomaterial
Bank Charite´ Berlin (ZeBanC, biobank.charite.de) that carries
out central processing of blood and saliva samples and storage
of DNA.
While numerous medical centers and institutions are
involved in various studies of the CNCHD, the CHD-
Biobank project is maintained by eight institutions: the depart-
ments of pediatric cardiology and/or heart surgery at the
University Hospitals of Kiel, Erlangen, Freiburg, and
Homburg, the University Heart Center of Leipzig, the Heart
Pickardt T et al / Biobank for Congenital Heart Defects 183and Diabetes Center NRW (Bad Oeynhausen), the German
Heart Centre Munich, and the German Heart Institute Berlin.
Further inclusion of more hospitals is scheduled. Participation
is bound to the implementation of all required workﬂows, and
the participating institutions conﬁrm the acceptance of CHD-
Biobank policies and standard operation procedures (SOPs),
based on a collaboration agreement.
Study population
The CHD-Biobank collects biomaterials from patients with
any diagnosed congenital heart defect. For reference analyses,
samples of patients’ parents (trios) and relatives (from families
with an accumulation of CHD) are also included
systematically.
Legal framework—ethics and data privacy
Based on an appropriate patient informed consent, approval
by eight ethics committees in Germany and a data privacy con-
cept (registered with the Berlin Ofﬁcial for Data Protection
and Freedom of Information/No. 531.390), NRCHD is legally
authorized to (i) receive and store medical data and samples
from all age groups for an indeﬁnite time, (ii) continuously
request latest medical reports from the attending physicians,
(iii) re-contact registered participants, (iv) hold the right to
use the data and samples collected, and (v) make register data
and samples available to interested scientists and research
institutions for future studies and within the scope of interna-
tional cooperation.
Protection of personal data
Primary patient codes (pseudonyms) are kept in a separate
database (PID-generator, see below) to prevent unauthorized
access to re-identifying information. All samples are tagged
with a second-level code that is designated only for internal
use, i.e., the processing and storage at the collaborating labo-
ratory facility, where staff members are not able to obtain
information on the identity of sample donors or their health
conditions. When samples or aliquots of samples are released
to research facilities, a third-level code is generated, impeding
the re-identiﬁcation of patients.
The use of data
The use of data by research institutions is subject to the
CNCHD policies and a material transfer agreement (MTA)
that commits data recipients to handle data according to legal
regulations and applicable laws, e.g., preventing third parties
from having access to or using samples and data.
Patients’ right of self-determination
The storage of samples is generally intended for an indeﬁnite
time and yet-to-deﬁne research purpose. In order to give patients
the opportunity to obtain a continuous update regarding the
CHD-Biobank’s research activities (and to withdraw their con-
sent, if required), the NRCHD has implemented a web-based
patient information platform (www.herzregister.de). Sampledonors can object to the CHD-Biobank’s storing and using their
data/samples at any time. Donors can opt between the
anonymization and deletion/destruction of data/samples.Database systems and ID management
In consistence with the NRCHD’s overall concept, the CHD-
Biobank applies a central patient and sample ID manage-
ment. Patient codes are generated by a so-called PID-
generator [20], a software program that creates 8-digit/
alphanumeric pseudonyms on the basis of the patients’
personally-identiﬁable information. The latter is divided into
hard and soft criteria and phonetic algorithms, thus ensuring
the unambiguity of a patient’s data upon pseudonymization.
The PID-generator allows a hospital-independent assignment
of patients and facilitates multicenter and longitudinal
investigations.
For clinical data and sample acquisition, the NRCHD uses
a 3-tier server architecture consisting of Oracle 10g, which is a
customized version of ixserv4 (ixmid Technologie GmbH,
www.ixmid.com), as the application layer, and a Tomcat
web server for the presentation layer. The database for bio-
materials includes a web frontend with a deﬁned form
structure that enables the acquisition of sample-related data
(reception, processing, quality, dissemination, tracking, etc.)
and facilitates the collection and management of samples from
several locations. Sample ID management is performed using
uniform barcode-labeling systems including barcoded sample
containers with unique alphanumeric codes.Clinical data
Clinical data for each participant are obtained via medical
reports (doctor’s letters) that are provided by the treating
physicians or by the patients themselves. A standardized data-
set is recorded from each patient upon registration. The
recorded data include (1) personal data: surname, birth name,
ﬁrst name, date of birth, sex, address and contact details,
familiar status and relations (acquisition of families), place
of birth including federal state, marital status, and nationality,
and (2) medical/phenotype data: maternal age at birth, gesta-
tional age, multiple pregnancy, birth weight, prenatal diagno-
sis of CHD, all congenital and acquired cardiovascular
diagnoses, procedures, and additional diseases/disorders. If
necessary for accuracy and data validation, further medical
ﬁndings, e.g., additional data of magnetic resonance imaging
(MRI)/echocardiographic analysis, are requested from the
treating physicians. In addition, medical reports are obtained
regularly to continuously update/complete the medical
database.
Medical data are coded according to (i) the International
Statistical Classiﬁcation of Diseases and Related Health
Problems 10th Revision (ICD-10) and (ii) the International
Paediatric and Congenital Cardiac Code (IPCCC) of the Inter-
national Society for Nomenclature of Pediatric and Congenital
Heart Disease comprising 206 different main diagnoses for
CHD (Table 1) in order to cover the high variability of
CHD phenotypes and conditions. For a rough classiﬁcation
we assign affected sample donors to 29 diagnosis groups (see
below, section ‘‘Current state of sample collection”).
Table 1 Comparison between ICD-10 and IPCCC for the
classiﬁcation of congenital heart defects
Diagnosis/treatment Code range for ICD-10 Code range for IPCC
Main diagnosis 70 206
Congenital cardiac
secondary diagnosis
69 204
Acquired cardiac
secondary diagnosis
108 218
Hereditary, fetal and
neonatal diagnosis
42 55
Extracardiac diagnosis All available codes N/A
Cardiac operations N/A 299
Cardiac interventions N/A 66
Note: ICD-10, International Statistical Classiﬁcation of Diseases and
Related Health Problems 10th Revision; IPCCC, International
Paediatric and Congenital Cardiac Code. ICD-10 codes overlap
between different categories.
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of samples
The CHD-Biobank collects EDTA-blood (Sarstedt S-
Monovette K3E 2.7/4.9/9.0 ml, depending on donor age) and
saliva samples (DNAGenotek/Oragene OG-500 and OG-575)
for the extraction of DNA, as well as cardiac tissue samples
(snap-freezing in liquid nitrogen). The latter are obtained
within the scope of open heart surgery during which fractions
of tissue accumulate, which would be disposed of otherwise.
Blood/saliva collection and DNA extraction
Twomeans of sample acquisition are in place. Process A is used
for the acquisition of blood and saliva samples from patients
that are already registered, and their relatives. Patients areCoded cryotubes with 
differently colored cap inserts
Tissue sample 
acquisition form
List of heart 
tissue types
(complete list 
in Figure 5)
Time of tissue 
removal
Time (minu
removal and
Figure 2 Tissue-sample collection kit
The complete list of heart tissue types can be found in Figure 5.contacted by the NMO and asked for participation in the
CHD-Biobank project. Adult patients or sample donors, after
returning written consent, receive a blood or saliva sample kit.
For blood taking, sample donors address a physician of their
choice. Blood or saliva samples are sent to ZeBanC. Process A
is most suitable for recruiting families and twins via direct con-
tact to participants of the NRCHD. On the other hand, Process
B is used for the acquisition of blood samples from patients not
yet taking part in the NRCHD. Collaborating hospitals are reg-
ularly provided by the NMOwith blood kits that include coded
documents (informed consent and sample data sheets) and bar-
coded sample containers that are linked to the respective docu-
ments (recorded in the CHD-Biobank database). Within the
scope of scheduled examinations, patients are informed and
blood withdrawal takes place if they agree. The responsible
physician forwards the signed consent form together with a
medical report to the NMO, and the blood sample to ZeBanC.
A small amount of blood sample is retained for control pur-
poses and stored at 80 C. Saliva and the remaining blood
samples are further processed at ZeBanC. For the automated
extraction of DNA from blood and saliva, ZeBanC uses the
Freedom EVO HSM 2.0 Workstation and the ReliaPrep Large
Volume HTgDNA Isolation System (Promega/Tecan). The
processing, aliquoting, and storage of samples are documented
via the online-accessible CHD-Biobank database. The docu-
mented data include information with respect to the date of
blood taking, dispatch and arrival, blood volume/quality,
extraction-related information/speciﬁcations, DNA purity,
gel-quality check, concentration, volume and aliquotting.
DNA is stored at 20 C.Tissue samples from open heart surgery
The NMO provides speciﬁc tissue sample kits (Figure 2) for
all participating departments. A sample kit comprises ﬁveTube-codes as 1D-barcodes 
for subsequent database entry 
Date of 
operation
Box for 
patient 
identifier 
label
tes) between 
 fixation start
Colored dot-arrays corresponding 
to the colored tube-cap inserts
Plastic 
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unique identiﬁer (2D + 1D barcodes), and a standardized
sample acquisition form, tagged with the identiﬁers of the
above tubes, printed as 1D-barcodes. Tubes and acquisition
form are therefore already linked prior to their usage.
Moreover, the acquisition form contains a list of heart
tissue types that have been pre-deﬁned by the Network
surgeons.
When tissue kits are allocated to a certain patient, the sur-
gical team can collect tissue samples without the need of fur-
ther marking/labeling tubes. The type of tissue that is placed
in one of the ﬁve tubes is readily designated: tube caps contain
inserts in different colors which are reproduced as dots along-
side the list of tissue types; then the corresponding dot just has
to be ticked on the acquisition form.
Samples are snap-frozen in liquid nitrogen and then stored
in the gas phase of liquid nitrogen. The samples are stored in
local facilities at the participating medical centers. All sample
data (vial code, type of tissue, acquisition date, position in
the nitrogen-storage container) are entered electronically via
web interface into the CHD-Biobank database.
Sample quality management
All workﬂows have been deﬁned in SOPs and are revised and
adjusted continuously according to technological progress.
SOPs conform to or are based on the International Society for
Biological and Environmental Repositories (ISBER) recom-
mendations (http://www.isber.org). The following measures
have been introduced in order to maintain high quality stan-
dards regarding the logistics and infrastructure of the CHD-
Biobank.
Uniform protocols and workﬂows
The NMO team provides an efﬁcient data and sample manage-
ment, the implementation of harmonized protocols and work-
ﬂows, standardized logistics, efﬁcient central administration,
and a continuous risk assessment.
Guideline-based patient contact
Recruitment of patients and families is accompanied by
substantial guideline-based telephone interviews performed
by NMO staff members that are speciﬁcally instructed
and allowed to initiate and hold contact to register
participants.
On-site visits
Participating hospitals are controlled through on-site visits by
NMO staff members at least once a year, including the instruc-
tion of hospital staff members involved in data and sample col-
lection, as well as documentation.
Permanent availability and support
The NMO team permanently keeps in touch with the respon-
sible hospital staff members and provides them with support.Web-based data entry
Information relevant to sample quality, acquisition, and
processing procedures is recorded in the online-accessible
CHD-Biobank database. The NMO team monitors data entry
in real time.
Use of 1D/2D barcodes
For nitrogen storage of samples, FluidX Cryovials with 2D-
barcode jackets are used. The identiﬁcation and recording of
samples occur via barcode reading (linear- and 2D-barcode
readers) only.
Secure nitrogen storage and handling
For tissue storage, the CHD-Biobank is equipped with
Cryotherm Biosafe 120 MD containers providing an online-
accessible, permanent all-over control and complete
documentation of temperature and nitrogen ﬁlling status.
For incorporating and disseminating samples, a working
procedure preventing thawing and refreezing has been
implemented.
Network policies and use of the sample collection
The NRCHD is a sustainable legal entity that is eligible to
receive, store, and use data and samples from patients with
CHD for research purposes. The sample donors transfer the
right to use their biomaterials for scientiﬁc purposes to the
NRCHD, which reserves the right to use as long as sample
donors do not withdraw their consent.
Use and access regulations and policies (see www.kompe-
tenznetz-ahf.de/en/research/initiating-new-projects) comprise
(i) general rules for cooperative studies, (ii) deﬁned forms/
templates for research proposals, (iii) a deﬁned description of
the decision process, and (iv) publication guidelines.
The CHD-Biobank offers researchers both the option of
using existing samples and associated demographic and medi-
cal data, as well as the option of utilizing the CHD-Biobank
infrastructure for a prospective recruitment of sample donors
for speciﬁc studies. This service is open to all researchers or sci-
entists with relevant expertise in the ﬁeld of genetics and CHD
and is not limited to members of the CNCHD.
In order to participate, researchers have to submit a
research proposal to the NMO. Research proposals are evalu-
ated by the Scientiﬁc Board, which consists of experts in the
ﬁelds of (pediatric) cardiology, epidemiology, human genetics,
basic research, biometry/statistics, and ethics/health care law.
Moreover, the Board comprises a representative of the
German umbrella organization for children with CHD
(BVHK e. V.). The ﬁnal decision is made by the Steering
Committee of the CNCHD and the representatives of the
institutions where the samples have been collected, based on
criteria such as a project’s feasibility, the precisely-deﬁned
objective, acceptance within the CHD research community,
and stringent scheduling. Appropriate expertise in the ﬁeld
of interest is therefore a prerequisite.
Upon approval, collaborating research groups and institu-
tions must agree to make, after completion and publication
Table 3 Distribution of the affected donors by diagnosis groups
Diagnosis group Number of the
aﬀected donors
1 Aortic coarctation 243
186 Genomics Proteomics Bioinformatics 14 (2016) 181–190of their study, exploitable data such as sequence data available
for being used by research groups in future studies.
Sustainability
Since January 2015, the NRCHD is supported by the newly
established German Center for Cardiovascular Research
(DZHK). Within this close cooperation, a comprehensive sus-
tainable research network could be established, which covers
congenital and acquired cardiovascular diseases in children
and adults.
Current state of sample collection
Table 2 gives an outline of the current DNA collection of the
CHD-Biobank (as of March 2016): the collection comprises
DNA samples from 4602 donors, including 2928 affected
donors, covering a wide range of CHD phenotypes. 1674
donors are non-affected relatives, since the CHD-Biobank
focuses on the inclusion of whole families when more than
one affected member is present, and the enrollment of trios
(affected children and their healthy parents). In addition to
family and trio samples, the inclusion of twins is crucial for
research on etiology and genetic factors of CHDs as well.
The CHD-Biobank recruits families and twins mainly by direct
contact to registered participants via Process A (as described in
section ‘‘Blood/saliva collection and DNA extraction”).
The breakdown of sample donors by age groups (Figure 3,
documented age when samples were taken) reveals the pre-Table 2 Outline of the current CHD-Biobank DNA collection
Participant classiﬁcation Number
Donors Aﬀected donors 2928
Non-aﬀected donors 1674
Families with 2 aﬀected members 102
3 aﬀected members 24
4 aﬀected members 3
Trios (patient plus
healthy parents)
453
Enrolled twin pairs Monozygotic 15
Dizygotic 19
Status still unknown 13
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163
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Figure 3 Age distribution of the affected donors
The age here refers to the documented age when samples were
taken.dominance of underage patients (0–17 years), which represent
more than 70% of the affected donors.
Table 3 shows the distribution of the 29 diagnosis groups
that we use for rough classiﬁcation of the affected donors.
The distribution does not reﬂect the average distribution of
CHDs, since the CHD-Biobank focuses mainly on medium
or severe, complex heart defects.
While the majority of children born with CHDs do not
have other birth defects (isolated CHD), 20%–30% of cases
occur in association with other, extracardiac anomalies or as
part of a syndrome (syndromic CHD). Figure 4 shows the dis-
tribution of syndromes/disorders among the affected donors in
the CHD-Biobank.
For DNA extraction, 9 ml of blood are withdrawn from
adults. In acordance with the German ethical guidelines
regarding underage participants, amounts of maximally 9 ml
(age 3–17), 5 ml (age 1–3), and 2.5 ml (below age 1) of blood
are taken. Moreover, the ethics commission speciﬁes that
blood to be used for scientiﬁc purposes may only be taken
from underage patients within the scope of a medical examina-
tion. We therefore additionally implemented saliva sample kits
(DNAGenotek, Oragene, standard amount of 2 ml saliva) for
DNA acquisition from affected, underage donors beyond med-
ical examinations and for non-affected siblings.2 Aortic valve abnormalities 201
3 Atrioventricular septal defect 177
4 Common arterial trunk 32
5 Complete transposition of great
arteries
105
6 Congenitally corrected transposition
of great arteries
61
7 Discordant VA connections 55
8 Double inlet left ventricle 73
9 Double outlet right ventricle 89
10 Ebstein’s malformation of tricuspid
valve
49
11 Hypoplastic left heart syndrome 189
12 Interatrial communication 345
13 Interrupted aortic arch 11
14 MARFAN Syndrome 11
15 Mitral atresia 9
16 Mitral valve abnormalities 21
17 Partially anomalous pulmonary
venous connection(s)
45
18 Patent arterial duct 115
19 Primary Cardiomyopathy 80
20 Pulmonary atresia + intact
ventricular septum
40
21 Pulmonary atresia + ventricular
septal defect
124
22 Pulmonary valve abnormalities 79
23 Shone Complex 9
24 Subaortic stenosis 12
25 Tetralogy of Fallot 279
26 Total anomalous pulmonary venous
connection
13
27 Tricuspid atresia 80
28 Ventricular septal defect 227
29 Other 154
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Figure 4 Distribution of the affected donors born with additional syndromes/disorders
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average yields 15.2 lg DNA from 1 ml EDTA-blood and
16.8 lg DNA from 1 ml of saliva. In addition to the routine
control via gel electrophoresis and absorbance ratios 260/280
and 260/230 nm, the quality of DNA from 1147 sample donors
has been checked within the scope of the cooperative project
with the Wellcome Trust Sanger Institute (WTSI, Cam-
bridge/UK). In more than 98% of samples, whole exome- or
panel-sequencing was successful.
Figure 5 shows the tissue samples that have been collected
so far at the heart surgery departments of the university hospi-
tals of Kiel, Erlangen, and Saarland/Homburg, as well as the
German Heart Institute in Berlin. In total, 1295 tissue samples
have been collected from 659 patients, which are listed in Fig-
ure 5 according to the tissue type. An RNA quality control
analysis of 20 tissue samples within the scope of our coopera-
tive project with the Department of Pediatric Cardiology and
Critical Care at Hannover Medical School revealed RNA
integrity number (RIN) values of 8.2–9.4, indicating a high
quality of the RNA generated.
Cooperative projects and partner institutions
At the time when the CHD-Biobank was initiated (2008/09),
research on CHD genetics was only slightly established in
Germany, partially due to the limited availability of samples.
We therefore started cooperative projects on an international
level from the beginning. A number of projects have since then
Table 4 Cooperative projects and partner institutions
Partner institutions Sample type CHD type /study No. of samples Status Refs.
Academic Medical Centre Amsterdam, the Netherlands; Institute
of Human Genetics, Newcastle University, UK; Heart Repair-
Consortium
DNA Complex CHD 78 Completed [21,22]
Department of Pediatric Cardiology, Friedrich-Alexander-
Universita¨t Erlangen-Nu¨rnberg
DNA CM 62 Completed [23]
Department of Congenital Heart Disease and Pediatric
Cardiology, University Hospital of Schleswig-Holstein, Campus
Kiel, and further international partner institutions
DNA CM 16 Completed [24]
Department of Cardiovascular Genetics, Experimental and
Clinical Research Center, Charite´ – Universita¨tsmedizin Berlin and
Max Delbru¨ck Center (MDC) for Molecular Medicine, Berlin,
Germany
DNA TOF families 35 Completed [25]
Wellcome Trust Sanger Institute, Cambridge/UK, and further
international partner institutions
DNA AVSD 18 Completed [26]
Department of Pediatric Cardiology, Friedrich-Alexander-
Universita¨t Erlangen-Nu¨rnberg
DNA CoA 83 Completed [27]
Institute of Biochemistry and Molecular Genetics, Ulm University DNA Heterotaxy 74 Completed Manuscript
submitted
Department of Cardiology and Pneumology, Go¨ttingen University DNA HLHS 72 In progress
Department of Pediatric Cardiology and Critical Care, Hannover
Medical School
Heart tissue TOF 36 In progress
Wellcome Trust Sanger Institute, Cambridge/UK and further
international partner institutions
DNA LVOTO 1147 Completed Manuscript
submitted
Note: CHD, congenital heart disease; CM, primary cardiomyopathy; TOF, tetralogy of Fallot; AVSD, atrioventricular septal defect; CoA, aortic
coarctation; HLHS, hypoplastic left heart syndrome; LVOTO, left ventricular outﬂow tract obstruction.
188 Genomics Proteomics Bioinformatics 14 (2016) 181–190been completed and further projects are in progress or in
preparation. Projects include candidate gene approaches,
chip-based copy number variation (CNV) analysis, and vari-
ous NGS approaches. Up to now, a total of 1588 DNA sam-
ples of the affected and non-affected donors, as well as 36
tissue samples from heart surgery, have been provided for var-
ious research studies (Table 4).
Conclusions
Research activities including molecular mechanisms of the
development of cardiovascular malformations and several
associated long-term morbidities are increasingly becoming a
substantial subject of genetic studies, largely due to sequencing
capacities being available and a more routine use of bioinfor-
matic analysis techniques.
The identiﬁcation of the causes and underlying molecular
genetic processes, and an improved understanding of the
pathologic mechanisms of long-term morbidities, are the pre-
requisites of developing new prevention strategies and treat-
ment methods for patients with CHD. In particular, for
patients with moderate and severe CHD in their early life,
morbidities after successful operative treatment are now chal-
lenging their long-term survival and quality of life. Unfortu-
nately, there are only scarce data on molecular mechanisms
underlying myocardial systolic and diastolic dysfunction and
possible therapeutic targets in the left and right ventricle.
Similarly, data from patients having a morphologically
single ventricle with heterogeneous anatomy are rare as well.
The genetic mechanisms underlying several extracardiac mor-
bidities, including hypoplasia and inadequate pulmonary
growth in patients with restricted pulmonary perfusion, rapidgrowth and dilatation of the ascended aorta in patients with
univentricular heart or tetralogy of Fallot and pulmonary
atresia, are currently unknown. Thus, prospective clinical
and genetic trials in larger cohorts are needed. These can only
be performed on the basis of a nationwide registry and
biobank.
The CHD-Biobank includes comprehensive representative
genetic materials of patients and their parents as well as
further relatives, covering severe and mild CHD. The Net-
work Management Team is currently increasing the efforts
to include more families with accumulation of congenital
cardiomyopathies.
The rising number of requests for collaboration from
numerous national and international research institutions
can be regarded as an indication for the high quality of sam-
ples and phenotype data deposited in our biobank.
The described biobank may represent a future platform for
prospectively recruiting cohorts of patients with complex
CHD, including the comprehensive phenotypic and genetic
characterization in early childhood, as well as repeated clinical
and cardiac follow-up and assessments at standardized time
intervals. Such an approach may be the basis to develop indi-
vidualized medical treatment and care for patients with these
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